{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:04:23Z","timestamp":1777435463279,"version":"3.51.4"},"reference-count":32,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,11]]},"DOI":"10.31744\/einstein_journal\/2025gs1301","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:55:18Z","timestamp":1758120918000},"source":"Crossref","is-referenced-by-count":1,"title":["Judicial demands for prostate cancer treatment in Brazil: androgen receptor pathway inhibitors are an urgent public health problem"],"prefix":"10.31744","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7034-9515","authenticated-orcid":false,"given":"Mariana Avelar da","family":"Silveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7555-2550","authenticated-orcid":false,"given":"Carla de Oliveira","family":"Ricomini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5809-0087","authenticated-orcid":false,"given":"Reuli Cordeiro da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6574-3866","authenticated-orcid":false,"given":"Flavio Tocci","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0634-7086","authenticated-orcid":false,"given":"Carlos Henrique Sartorato","family":"Pedrotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-6037","authenticated-orcid":false,"given":"Vanessa Damazio","family":"Teich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-044X","authenticated-orcid":false,"given":"Luciana Holtz de Camargo","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9053-5046","authenticated-orcid":false,"given":"Sidney","family":"Glina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-4345","authenticated-orcid":false,"given":"Fernando","family":"Korkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"key":"key20250917145514_B1","volume-title":"Lei n\u00ba 8.080, de 19 de setembro de 1990. Disp\u00f5e sobre as condi\u00e7\u00f5es para a promo\u00e7\u00e3o, prote\u00e7\u00e3o e recupera\u00e7\u00e3o da sa\u00fade, a organiza\u00e7\u00e3o e o funcionamento dos servi\u00e7os correspondentes e d\u00e1 outras provid\u00eancias","author":"Brasil. Presid\u00eancia da Rep\u00fablica","year":"1990","unstructured":"1 Brasil. Presid\u00eancia da Rep\u00fablica. Lei n\u00ba 8.080, de 19 de setembro de 1990. Disp\u00f5e sobre as condi\u00e7\u00f5es para a promo\u00e7\u00e3o, prote\u00e7\u00e3o e recupera\u00e7\u00e3o da sa\u00fade, a organiza\u00e7\u00e3o e o funcionamento dos servi\u00e7os correspondentes e d\u00e1 outras provid\u00eancias. Bras\u00edlia (DF): Presid\u00eancia da Rep\u00fablica; 1990 [citado 2024 Mar 8]. Dispon\u00edvel em: https:\/\/www.planalto.gov.br\/ccivil_03\/leis\/l8080.htm"},{"key":"key20250917145514_B2","volume-title":"Sistema \u00danico de Sa\u00fade","author":"Brasil. Minist\u00e9rio da Sa\u00fade","year":"2024","unstructured":"2 Brasil. Minist\u00e9rio da Sa\u00fade. Sistema \u00danico de Sa\u00fade. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2024 [citado 2024 Mar 8]. Dispon\u00edvel em: http:\/\/www.gov.br\/saude\/pt-br\/assuntos\/saude-de-a-a-z\/s\/sus"},{"issue":"8","key":"key20250917145514_B3","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1590\/1413-81232017228.07982017","article-title":"Demandas judiciais por medicamentos antineopl\u00e1sicos: a ponta de um iceberg?","volume":"22","author":"Vidal","year":"2017","unstructured":"3 Vidal TJ, Moraes EL, Retto MP, Silva MJ. Demandas judiciais por medicamentos antineopl\u00e1sicos: a ponta de um iceberg? Cien Saude Colet. 2017;22(8):2539-48.","journal-title":"Cien Saude Colet"},{"key":"key20250917145514_B4","volume-title":"Judici\u00e1rio vai avaliar impacto das notas t\u00e9cnicas de sa\u00fade nas decis\u00f5es judiciais","author":"Justi\u00e7a Federal da 2\u00aa Regi\u00e3o","year":"2023","unstructured":"4 Justi\u00e7a Federal da 2\u00aa Regi\u00e3o. Judici\u00e1rio vai avaliar impacto das notas t\u00e9cnicas de sa\u00fade nas decis\u00f5es judiciais. Rio de Janeiro (RJ): TRF2; 2023 [citado 2023 Dez 2]. Dispon\u00edvel em: https:\/\/www10.trf2.jus.br\/portal\/judiciario-vai-avaliar-impacto-das-notas-tecnicas-de-saude-nas-decisoes-judiciais\/"},{"issue":"1","key":"key20250917145514_B5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/s1677-5538.ibju.2023.0539","article-title":"Focal therapy: overcoming barriers for advances in prostate cancer treatment in South America","volume":"50","author":"Ezequiel","year":"2024","unstructured":"5 Ezequiel B, Marcelo B, Polascik T, Rastineshad A, Rodriguez-Sanchez L, Sanchez-Salas R. Focal therapy: overcoming barriers for advances in prostate cancer treatment in South America. Int Braz J Urol. 2024;50(1):100-4.","journal-title":"Int Braz J Urol"},{"issue":"44","key":"key20250917145514_B6","first-page":"1","article-title":"Differences in systemic cancer treatment in Brazil: my Public Health System is different from your Public Health System","volume":"13","author":"Kaliks","year":"2017","unstructured":"6 Kaliks RA, Matos TF, Silva VA, Barros LH. Differences in systemic cancer treatment in Brazil: my Public Health System is different from your Public Health System. Braz J Oncol. 2017;13(44):1-12.","journal-title":"Braz J Oncol"},{"key":"key20250917145514_B7","volume-title":"Torna p\u00fablica a decis\u00e3o de incorporar a abiraterona para o c\u00e2ncer de pr\u00f3stata metast\u00e1tico resistente \u00e0 castra\u00e7\u00e3o de pacientes com uso pr\u00e9vio de quimioterapia, conforme a Assist\u00eancia Oncol\u00f3gica no SUS, no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS","author":"Brasil. Minist\u00e9rio da Sa\u00fade. Portaria n\u00ba 38, de 25 de julho de 2019","year":"2019","unstructured":"7 Brasil. Minist\u00e9rio da Sa\u00fade. Portaria n\u00ba 38, de 25 de julho de 2019. Torna p\u00fablica a decis\u00e3o de incorporar a abiraterona para o c\u00e2ncer de pr\u00f3stata metast\u00e1tico resistente \u00e0 castra\u00e7\u00e3o de pacientes com uso pr\u00e9vio de quimioterapia, conforme a Assist\u00eancia Oncol\u00f3gica no SUS, no \u00e2mbito do Sistema \u00danico de Sa\u00fade - SUS. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2019 [citado 2024 mar 8]. Dispon\u00edvel em: https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/sctie\/2019\/prt0038_25_07_2019.html"},{"issue":"8","key":"key20250917145514_B8","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.1519","article-title":"Challenges and opportunities in prostate cancer surgery in South America: insights into robot-assisted radical prostatectomies-A perspective","volume":"6","author":"Bharadwaj","year":"2023","unstructured":"8 Bharadwaj HR, Wireko AA, Adebusoye FT, Ferreira T, Pacheco-Barrios N, Abdul-Rahman T, et al. Challenges and opportunities in prostate cancer surgery in South America: insights into robot-assisted radical prostatectomies-A perspective. Health Sci Rep. 2023;6(8):e1519.","journal-title":"Health Sci Rep"},{"key":"key20250917145514_B9","first-page":"495","article-title":"An\u00e1lise de oportunidades de melhoria do acesso dos pacientes com c\u00e2ncer de pr\u00f3stata ao tratamento com radioterapia","volume":"41","author":"Linhares","year":"2021","unstructured":"9 Linhares AB, Lara RL, Etges AP, Zardo L, Cardoso RB, Nascimento TL, et al. An\u00e1lise de oportunidades de melhoria do acesso dos pacientes com c\u00e2ncer de pr\u00f3stata ao tratamento com radioterapia. Clin Biomed Res. 2021;41(Suppl):495-6.","journal-title":"Clin Biomed Res"},{"key":"key20250917145514_B10","volume-title":"SUS n\u00e3o tem como oferecer imunoterapia contra o c\u00e2ncer","author":"Varella","year":"2018","unstructured":"10 Varella D. SUS n\u00e3o tem como oferecer imunoterapia contra o c\u00e2ncer. Rio de Janeiro: O Globo; 2018. [citado 2024 Mar 8]. Dispon\u00edvel em: https:\/\/oglobo.globo.com\/saude\/drauzio-varella-sus-nao-tem-como-oferecer-imunoterapia-contra-cancer-22768927"},{"issue":"6","key":"key20250917145514_B11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1464-410X.2011.10365.x","article-title":"The economic burden of prostate cancer","volume":"108","author":"Roehrborn","year":"2011","unstructured":"11 Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 2011;108(6):806-13.","journal-title":"BJU Int"},{"issue":"2","key":"key20250917145514_B12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/pcan.2009.63","article-title":"A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer","volume":"13","author":"Crawford","year":"2010","unstructured":"12 Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(2):162-7.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key20250917145514_B13","volume-title":"Secretaria de Ci\u00eancia, Tecnologia, Inova\u00e7\u00e3o e Insumos Estrat\u00e9gicos em Sa\u00fade. Rela\u00e7\u00e3o Nacional de Medicamentos Essenciais : Rename 2024","author":"Brasil. Minist\u00e9rio da Sa\u00fade","year":"2024","unstructured":"13 Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia, Inova\u00e7\u00e3o e Insumos Estrat\u00e9gicos em Sa\u00fade. Rela\u00e7\u00e3o Nacional de Medicamentos Essenciais : Rename 2024. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2024 [citado 2023 Dez 2]. Dispon\u00edvel em: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/relacao_nacional_medicamentos_2024.pdf"},{"key":"key20250917145514_B14","volume-title":"C\u00e2mara de Regula\u00e7\u00e3o do Mercado de Medicamentos (CMED)","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)","year":"2025","unstructured":"14 Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). C\u00e2mara de Regula\u00e7\u00e3o do Mercado de Medicamentos (CMED). Bras\u00edlia (DF): ANVISA; 2025 [citado 2023 Dez 3]. Dispon\u00edvel em: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/cmed"},{"issue":"6","key":"key20250917145514_B15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1590\/s1677-5538.ibju.2015.0690","article-title":"Prostate cancer in Brazil and Latin America: epidemiology and screening","volume":"42","author":"Tourinho-Barbosa","year":"2016","unstructured":"15 Tourinho-Barbosa RR, Pompeo AC, Glina S. Prostate cancer in Brazil and Latin America: epidemiology and screening. Int Braz J Urol. 2016;42(6):1081-90.","journal-title":"Int Braz J Urol"},{"issue":"0","key":"key20250917145514_B16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1590\/s1518-8787.2017051006766","article-title":"Patient survival and risk of death after prostate cancer treatment in the Brazilian Unified Health System","volume":"51","author":"Braga","year":"2017","unstructured":"16 Braga SF, Souza MC, Oliveira RR, Andrade EIG, Acurcio FA, Cherchiglia ML. Patient survival and risk of death after prostate cancer treatment in the Brazilian Unified Health System. Rev Saude Publica. 2017;51(0):46.","journal-title":"Rev Saude Publica"},{"key":"key20250917145514_B17","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0277-2021","article-title":"Prostate cancer mortality in Brazil 1990-2019: geographical distribution and trends","volume":"55","author":"Iser","year":"2022","unstructured":"17 Iser DA, Cobalchini GR, Oliveira MM, Teixeira R, Malta DC, Naghavi M, Iser et al. Prostate cancer mortality in Brazil 1990-2019: geographical distribution and trends. Rev Soc Bras Med Trop. 2022;55(Suppl 1):e0277.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"key20250917145514_B18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.gaceta.2020.12.035","article-title":"Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component","volume":"36","author":"Ibarrondo","year":"2022","unstructured":"18 Ibarrondo O, Lizeaga G, Mart\u00ednez-Llorente JM, Larra\u00f1aga I, Soto-Gordoa M, \u00c1lvarez-L\u00f3pez I. Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component. Gac Sanit. 2022;36(3):246-52.","journal-title":"Gac Sanit"},{"key":"key20250917145514_B19","volume-title":"Ju\u00edzes e ju\u00edzas podem acessar notas t\u00e9cnicas sobre sa\u00fade","author":"Escola Judicial Desembargador Ed\u00e9sio Fernandes (EJEF)","year":"2025","unstructured":"19 Escola Judicial Desembargador Ed\u00e9sio Fernandes (EJEF). Ju\u00edzes e ju\u00edzas podem acessar notas t\u00e9cnicas sobre sa\u00fade. Minas Gerais: Ejef; 2025 [citado 2023 Dez 5]. Dispon\u00edvel em: https:\/\/ejef.tjmg.jus.br\/e-natjus-disponibiliza-novas-funcionalidades\/"},{"key":"key20250917145514_B20","volume-title":"Justi\u00e7a leva em m\u00e9dia um ano para dar resposta a processos de sa\u00fade","author":"Ag\u00eancia Brasil","year":"2023","unstructured":"20 Ag\u00eancia Brasil. Justi\u00e7a leva em m\u00e9dia um ano para dar resposta a processos de sa\u00fade. Bras\u00edli (DF): Ag\u00eancia Brasil; 2023 [citado 2023 Dez 5]. Dispon\u00edvel em: https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2023-05\/justica-leva-em-media-um-ano-para-dar-resposta-a-processos-de-saude"},{"key":"key20250917145514_B21","volume-title":"CNJ promove evento para debater as demandas da sa\u00fade no Judici\u00e1rio","author":"Consultor Jur\u00eddico","year":"2022","unstructured":"21 Consultor Jur\u00eddico. CNJ promove evento para debater as demandas da sa\u00fade no Judici\u00e1rio. S\u00e3o Paulo: ConJur; 2022 [citado 2023 Dez 5]. Dispon\u00edvel em: https:\/\/www.conjur.com.br\/2022-nov-17\/cnj-promove-evento-debater-demandas-saude-judiciario\/"},{"key":"key20250917145514_B22","volume-title":"Impactos da judicializa\u00e7\u00e3o da sa\u00fade s\u00e3o debatidos no I Congresso do Fonajus","author":"Conselho Nacional de Justi\u00e7a (CNJ)","year":"2022","unstructured":"22 Conselho Nacional de Justi\u00e7a (CNJ). Impactos da judicializa\u00e7\u00e3o da sa\u00fade s\u00e3o debatidos no I Congresso do Fonajus. Bras\u00edlia (DF): CNJ; 2022 [citado 2023 Dez 5]. Dispon\u00edvel em: https:\/\/www.cnj.jus.br\/impactos-da-judicializacao-da-saude-sao-debatidos-no-i-congresso-do-fonajus\/"},{"key":"key20250917145514_B23","volume-title":"Funda\u00e7\u00e3o Oswaldo Cruz (Fiocruz). FiscSa\u00fade \u00e9 divulgado pelo Tribunal de Contas da Uni\u00e3o com an\u00e1lise sobre o sistema de sa\u00fade brasileiro - Desigualdade regional pesa no SUS","author":"PenseSUS","year":"2014","unstructured":"23 PenseSUS. Funda\u00e7\u00e3o Oswaldo Cruz (Fiocruz). FiscSa\u00fade \u00e9 divulgado pelo Tribunal de Contas da Uni\u00e3o com an\u00e1lise sobre o sistema de sa\u00fade brasileiro - Desigualdade regional pesa no SUS. Rio de Janeiro: PenseSUS; Fiocruz; 2014 [citado 2024 Mar 8]. Dispon\u00edvel em: https:\/\/pensesus.fiocruz.br\/desigualdade-regional-pesa-no-sus"},{"key":"key20250917145514_B24","volume-title":"NCCN Guidelines. Prostate Cancer","author":"National Comprehensive Cancer Network (NCCN)","year":"2024","unstructured":"24 National Comprehensive Cancer Network (NCCN). NCCN Guidelines. Prostate Cancer. Plymouth Meeting (PA): NCCN; 2024 [cited 2023 Dec 2]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459"},{"issue":"10","key":"key20250917145514_B25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36604","article-title":"Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy","volume":"6","author":"Corsini","year":"2023","unstructured":"25 Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy. JAMA Netw Open. 2023;6(10):e2336604.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"key20250917145514_B26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","unstructured":"26 James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O\u2019Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338-51.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20250917145514_B27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","unstructured":"27 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-60.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20250917145514_B28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","unstructured":"28 Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Ju\u00e1rez Soto \u00c1, Merseburger AS, \u00d6zg\u00fcro\u011flu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20250917145514_B29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","unstructured":"29 Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121-31.","journal-title":"N Engl J Med"},{"key":"key20250917145514_B30","volume-title":"Pr\u00f3stata","author":"Radar do C\u00e2ncer","year":"2024","unstructured":"30 Radar do C\u00e2ncer. Pr\u00f3stata. Radar do C\u00e2ncer; 2024 [citado 2023 Dez 2]. Dispon\u00edvel em: https:\/\/www.radardocancer.org.br\/cancer-prostata"},{"key":"key20250917145514_B31","doi-asserted-by":"crossref","first-page":"1756287219872324","DOI":"10.1177\/1756287219872324","article-title":"Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery","volume":"11","author":"de C\u00e1ssio Zequi","year":"2019;","unstructured":"31 de C\u00e1ssio Zequi S, da Costa WH, Korkes F, Dos Reis RB, Busato WF, Matheus WE, et al. Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery. Ther Adv Urol. 2019;11:1756287219872324.","journal-title":"Ther Adv Urol"},{"issue":"4","key":"key20250917145514_B32","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1590\/1413-81232017224.26862016","article-title":"Regional health inequalities: changes observed in Brazil from 2000-2016","volume":"22","author":"Albuquerque","year":"2017","unstructured":"32 Albuquerque MV, Viana AL, Lima LD, Ferreira MP, Fusaro ER, Iozzi FL. Regional health inequalities: changes observed in Brazil from 2000-2016. Cien Saude Colet. 2017;22(4):1055-64.","journal-title":"Cien Saude Colet"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:55:23Z","timestamp":1758120923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/judicial-demands-for-prostate-cancer-treatment-in-brazil-androgen-receptor-pathway-inhibitors-are-an-urgent-public-health-problem\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"alternative-id":["10.31744\/einstein_journal\/2025GS1301"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2025gs1301","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"eGS1301"}}